PT  - JOURNAL ARTICLE
AU  - Saito, Tetsuya
AU  - Inohara, Taku
AU  - Tsuruta, Hikaru
AU  - Yashima, Fumiaki
AU  - Shimizu, Hideyuki
AU  - Fukuda, Keiichi
AU  - Ohno, Yohei
AU  - Nishina, Hidetaka
AU  - Nakajima, Yoshifumi
AU  - Izumo, Masaki
AU  - Asami, Masahiko
AU  - Naganuma, Toru
AU  - Mizutani, Kazuki
AU  - Yamawaki, Masahiro
AU  - Tada, Norio
AU  - Yamanaka, Futoshi
AU  - Shirai, Shinichi
AU  - Noguchi, Masahiko
AU  - Ueno, Hiroshi
AU  - Takagi, Kensuke
AU  - Watanabe, Yusuke
AU  - Yamamoto, Masanori
AU  - Hayashida, Kentaro
AU - the OCEAN-TAVI investigators
TI  - Pre-existing left bundle branch block and clinical outcomes after transcatheter aortic valve replacement
AID  - 10.1101/2023.04.06.23288271
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.04.06.23288271
4099  - http://medrxiv.org/content/early/2023/04/09/2023.04.06.23288271.short
4100  - http://medrxiv.org/content/early/2023/04/09/2023.04.06.23288271.full
AB  - Background There are currently few reports on pre-existing left bundle branch block (LBBB) in patients undergoing transcatheter aortic valve replacement (TAVR). Nor are there any studies comparing patients with new onset LBBB to those with pre-existing LBBB. This study aimed to investigate the association with pre-existing or new-onset LBBB and clinical outcomes after TAVR.Methods Using data from the Japanese multicenter registry, 5996 patients who underwent TAVR between October 2013 and December 2019 were included. Patients were classified into 3 groups: no LBBB, pre-existing LBBB and new onset LBBB. The 2-year clinical outcomes were compared between 3 groups using Cox proportinal hazard models and propensity score analysis to adjust the differences in baseline characteristics.Results Of 5996 patients who underwent TAVR, 280 patients (4.6%) had pre-existing LBBB and new onset LBBB occurred in 1658 patients (27.6%). Compared with no LBBB group, multivariable Cox regression analysis showed that pre-existing LBBB was associated with a higher 2-year all-cause (adjusted hazard ratio [aHR]: 1.39; 95% confidence interval [CI]: 1.06-1.82; p =0.015) and cardiovascular mortality (aHR: 1.62; 95% CI: 1.05-2.54; p =0.027), but also with higher all-cause (aHR:1.43, 95% CI:1.07-1.91; p =0.016) and cardiovascular mortality (aHR: 1.84, 95% CI: 1.14-2.98; p =0.012) than new onset LBBB group. Heart failure was the most common cause of cardiovascular death, with more heart failure deaths in the pre-existing LBBB group.Conclusions Pre-existing LBBB was independently associated with poor clinical outcomes reflecting increased risk of cardiovascular mortality after TAVR. Patients with pre-existing LBBB should be carefully monitored.What is Known?There are currently few reports on pre-existing left bundle branch block (LBBB) in patients undergoing transcatheter aortic valve replacement (TAVR). Nor are there any studies comparing patients with new onset LBBB to those with pre-existing LBBB.What the Study Add?Patients with pre-existing LBBB not only had a higher mortality than those without LBBB, but also had a worse prognosis than those with new onset LBBB.This was because patients with pre-existing LBBB had more heart failure deaths.Patients with pre-existing LBBB should be carefully monitored after TAVR. Further investigation will be required to corroborate our findings.Competing Interest StatementDr. Takagi, Dr. Shimizu are clinical proctors for Edwards Lifesciences. Dr. Asami, Dr. Ohno and Dr. Yashima are clinical proctors for Medtronic. Dr. Ueno, Dr. Tada, Dr. Naganuma, Dr. Mizutani, and Dr. Watanabe are clinical proctors for Edwards Lifesciences and Medtronic. Dr. Hayashida, Dr. Yamamoto, and Dr. Shirai are clinical proctors for Edwards Lifesciences, Abbott Medical, and Medtronic. The remaining authors have nothing to disclose.Clinical TrialUMIN-ID: 000020423Funding StatementThe OCEAN-TAVI registry is supported by Edwards Lifesciences, Medtronic, Boston Scientific, Abbott Medical, and Daiichi-Sankyo company.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The OCEAN-TAVI registry was registered with the University Hospital Medical Information Network Clinical Trial Registry and accepted by the International Committee of Medical Journal Editors (UMIN-ID: 000020423). All study participants provided informed consent, and the registry was approved by the ethics committees of all participating institutions. Patients were followed annually at the participating institutions.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Not ApplicableThe data underlying this article will be shared on reasonable request.ASaortic stenosisCIconfidence intervalHRhazard ratioLBBBleft bundle branch blockTAVRtranscatheter aortic valve replacement